Document:

EX-10.1

 Exhibit 10.1 

Execution Copy 
 THIRD AMENDMENT
TO EMPLOYMENT AGREEMENT 
 THIS THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”) is entered into
this 1st day of April, 2018 (the “Amendment Date”), by and between COMMERCIAL METALS COMPANY, a Delaware corporation (“Employer”), and
TRACY L. PORTER (“Executive”). 
 RECITALS: 

    WHEREAS, the Employer and Executive originally entered into that certain Employment Agreement (the
“Agreement”), dated as of April 19, 2010, and further amended the Agreement as of May 27, 2015 and September 30, 2016; and 

WHEREAS, the Employer and Executive desire to further amend the Agreement in recognition of Executive’s promotion to the position
of Executive Vice President and Chief Operating Officer of the Employer effective April 1, 2018; 
 A G R E E M E N T 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants herein contained, it is agreed as follows: 

1.    Definitions. All undefined terms when used herein shall have the same respective meanings as are given such terms in
the Agreement, as amended, unless expressly provided otherwise in this Amendment. 
 2.    Amendment. This
Amendment hereby amends and restates in their entirety Sections 1. Purpose, 5. Duties and Responsibilities, 6(a) Salary, and 19. Notices of the Agreement, as amended to date, with the following revised Sections 1.,
5., 6(a) and 19.: 
  

	 	1.	Purpose. The purpose of this Agreement is to formalize the terms and conditions of Executive’s employment with the Employer as Executive Vice President and Chief Operating Officer
effective April 1, 2018. This Agreement may only be amended by a writing signed by both Parties. 

  

	 	5.	Duties and Responsibilities. Upon execution of this Agreement, Executive shall diligently render his services to the Employer as Executive Vice President and Chief Operating Officer in accordance
with the Employer’s directives, and shall use his best efforts and good faith in accomplishing such directives. Executive shall report directly to the President and Chief Executive Officer of the Employer. Executive agrees to devote his
full-time efforts, abilities, and attention (defined to mean not normally less than forty (40) hours/week) to the business of the Employer, and shall not engage in any activities which will interfere with such efforts. 

 

	 	6.	a. Salary. Executive shall receive an annual base salary of not less than $700,000.00 during the term of this Agreement. This salary may be increased at the sole discretion of Employer, and
may not be decreased without Executive’s written consent. Notwithstanding the foregoing, Executive may voluntarily decrease his salary at any time. 

	 	19.	Notices. All notices pursuant to this Agreement shall be in writing and sent certified mail, return receipt requested, addressed as follows: 

 

					
		 	 Executive:
	  	 Employer:
  

		 	 Tracy L. Porter
	  	 Commercial Metals Company

		 	 6201 Southwind Lane
	  	 Attention: General Counsel

		 	 McKinney, Texas 75070
	  	 6565 North MacArthur Blvd.,

		 		  	 Suite 800

		 		  	Irving, Texas 75039
		 		  	Fax: 214.689.4326

 3.    No Other Modifications. Except as otherwise provided herein, all other terms and
provisions of the Agreement shall remain in full force and effect, unmodified by this Amendment.  
 4.    Binding
Agreement. The provisions of this Amendment shall be binding upon and inure to the benefit of the heirs, representatives, successors and permitted assigns of the Parties. 

5.    Authority. The Parties represent and warrant that they have the requisite authority to bind the party on whose behalf
they are signing. 
 6.    Counterparts. This Amendment may be executed in any number of original counterparts. Any such
counterpart, when executed, shall constitute an original of this Amendment, and all such counterparts together shall constitute one and the same Amendment. Either party may deliver its signature to the other via facsimile, or electronic (PDF)
transmission, and any signature so delivered shall be binding on the delivering Party. 
 7.    Voluntary Amendment. The
Parties have read this Amendment, and on the advice of counsel they have freely and voluntarily entered into this Amendment. 
 [Signature
Page to Follow] 

  
 2 

 IN WITNESS WHEREOF, the Parties have entered into this Amendment as of the Amendment Date
as defined above. 
  

			
	EXECUTIVE:
	
	 /s/ Tracy L/ Porter

	TRACY L. PORTER
	
	EMPLOYER:
	
	COMMERCIAL METALS COMPANY
		
	By:	 	 /s/ Barbara R. Smith

		 	Barbara R. Smith
		 	President and Chief Executive Officer

  
 3February
7, 2018

 

Todd
Caven, CFO

Regen
BioPharma Inc.

4700
Spring Street, Suite 304

La
Mesa, CA 91942

 

Dear
Todd:

 

The
purpose of this letter is to confirm the following details of our recent phone conversation. This is to confirm our conversation
this morning that Zander is willing and able to pre-pay our June 2018 anniversary license fee early in exchange for a reduced
cost of $90,000 (a $10,000 savings to Zander).

 

The
terms discussed were as follows:

 

		(1)	Pursuant
                                         to Section 3.1.2 of that License Agreement by and between Zander Therapeutics, Inc. and
                                         Regen Biopharma, Inc.(“Agreement”) , Zander is obligated to pay to Regen
                                         an annual non-refundable payment of $100,000 on each anniversary date of the Agreement
                                         (“Annual Anniversary Fee”)

		(2)	Zander,
                                         by making payment of $90,000 on or before February 10, 2018, shall have fully satisfied
                                         its June 2018 Annual Anniversary Fee obligation.

 

Zander
is happy to move forward on this transaction immediately. Please sign below in agreement to these terms and return to me. I will
consummate this transaction as soon as I receive your executed agreement.

 

 

Sincerely,

 

/s/David
Koos

David
Koos

Chairman
& CEO

 

Agreed
to by:

 

/s/Todd
S. Caven

Todd
S. Caven

Chief
Financial Officer

Regen
Biopharma, Inc.SECURITIES PURCHASE AGREEMENT

 

 

THIS SECURITIES PURCHASE AGREEMENT (the
“Agreement”) is entered into by and among Zander Therapeutics, Inc., a Nevada corporation (the “Company”)
whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and the Lloyd Eric Cotson Trust ( a California Revocable
Trust as amended and completely restated June 8, 2016) whose address is 1880 Veteran Ave, Suit #310, Los Angeles CA .

 

WHEREAS:

 

The Purchaser desires to shares of common
stock in the Company (“Shares”) in accordance with the terms and conditions set forth herein.

 

The Company desires to issue and sell
Shares to the Purchaser in accordance with the terms and conditions set forth herein.

 

THEREFORE, IT IS AGREED AS FOLLOWS

 

 

1. Purchase Price

 

The purchase price per Share (“Purchase Price”),
payable in US Dollars, shall be $2.00 per Share.

 

 

2. Form of Payment

 

The Purchaser shall pay the Purchase
Price per Share multiplied by that number of Shares Purchased by wire transfer of immediately available funds to the Company

WIRE INSTRUCTIONS:

__________________

__________________

 

3. Issuance of Shares

 

5 business days subsequent to receipt
of payment of the Purchase Price the Company shall issue to the Purchaser that number of Shares purchased

4. Purchaser’s Representations and Warranties

 

	 	(a)	As of the date hereof, the Purchaser is purchasing the Shares for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended (the “Act”). 

 

	 	(b)	The Purchaser is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under the Act

 

	 	(c)	The Purchaser and its advisors, if any, have been, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Shares which have been requested by the Purchaser or its advisors. Notwithstanding the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to such disclosure to the Purchaser.

 

    	 	1	 

     

    

 

	 	(d)	Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

	 	(e)	The execution, delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser’s breach of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Purchaser is a party, or by which Purchaser is or may be bound.

 

5. Company’s representations and warranties

 

a) Company is a corporation duly organized, validly existing
and in good standing under the laws of the state its incorporation and has the requisite corporate power and authority to enter
into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify,
any person, entity or governmental agency which consent has not been obtained.

(b) The execution, delivery and
performance of this Agreement by Company does not and shall not constitute Company’s breach of any statute or regulation
or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms,
conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a
party, or by which Company is or may be bound.

6. Restricted Securities Acknowledgement

 

Purchaser acknowledges that any
securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act of 1933 shall constitute
“restricted securities” as that term is defined in Rule 144 promulgated under the Act, and shall contain the following
restrictive legend:

“THESE SECURITIES HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF ANY STATE AND MAY NOT
BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH
LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED
TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”

8. Entire Agreement

This Agreement constitutes a final
written expression of all the terms of the Agreement between the parties regarding the subject matter hereof, are a complete and
exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings, and representations
between the parties.

9. Governing Law, Venue, Waiver of Jury Trial

All questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the
internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in California for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein and hereby irrevocably waives,
and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding. If either party shall
commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding
shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.

    	 	2	 

     

    

 

 

IN WITNESS WHEREOF, the parties have hereunto executed
this Agreement on the 30th day of January 2018.

	Zander Therapeutics, Inc	 
	 	 
	/s/ David Koos	 
	David Koos, CEO	 
	Date: 1/29/2018	 

 

	Purchaser	 
	 	 
	/s/Lloyd Eric  Cotson 	 
	Loyd Eric Cotson, Trustee	 
	 	 
	 	 
	 	 
	Date: 1/27/2018	 
	Number of Shares Purchased: 100,000
	Total Purchase Price: $200,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]